待处理
入排:排除
图源:待检查
Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial.
Carlos Toribio-Vázquez, Luis Martinez-Piñeiro
Eur Urol 85(3) 306
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板